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Abstract: Oral contraceptive pills are problems for women, often have many effects, 
and may cause several diseases. The purpose of this research was to determine the 
impact of oral contraceptive pills on factor V sufferers. This case-control study 
conducted in Khartoum Sudan during the period from April to November 2018. The 
study included 50 women who used oral contraceptive as a case and 50 women who 
did not use oral contraceptive pills as a control, all of whom were verbally informed of 
the study and approved for participation. The PCR do for each sample. The results 
obtained from cases show that the mean age is 30±5.5 and divided into three groups 
less than 20 with a lower frequency of 4 % (2/50), (20-35) with a higher incidence of 
80 % (40/50) and a higher rate of 16 % (8/50) for more than 35 years. Most cases 
use the oral contraceptive pill for more than one year at a frequency of 60% (30/50) 
with a mean of 2±0.8. The most frequent oral contraceptive pill use was 
levonorgestrel 88% (44/50), followed by desogestrel 12% (6/50). The study 
concludes that there is no significant difference in gene mutation between case and 
control. There was also an insignificant association between the mutation and 
demographic data. 
Keywords: factor V Leiden; oral contraceptive; mutation; a polymerase chain 
reaction  
 
INTRODUCTION 
 Oral contraceptives (OCs), also known as pills, are the most popular form of 
contraception (Dhont, 2010). The critical mechanism of action is ovulation 
suppression, and, besides, the oral contraceptive produces endometrium that is not 
receptive to ovum implantation and cervical mucus that has become dense and 
hostile to sperm transport(Hall et al., 2010). 
 Various types of oral contraceptives exist; combined oral contraceptives 
(COCs) containing estrogen and progestin (Kiley and Hammond, 2007), and 
Progestin-only contraception (POPs) containing progestin but no estrogen-containing 
this drug referred to as a mini-pill (Adamopoulou & Vgenopoulou, 2015; Renner & 
Edelman, 2016). 
 Oral contraceptive estrogen raises the number of clotting factors (II, VII, XII, 
VIII) in plasma (van Rooijen et al., 2002), Fibrinogen and thrombin activable 
fibrinolysis inhibitors by influencing gene transcription of different proteins (Hoppe, 
2014). Estrogen crosses a cell membrane for a specific target tissue within a 
cytoplasm attached to a nuclear receptor (Bassett et al., 2003). Estrogen – an atomic 
receptor complex then moves to the nucleus where it identifies and binds to unique 
recognition sites that contribute to gene transcription by allowing RNA Polymerase II 
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to transcribe proteins to that DNA region in this case, new proteins are the 
coagulation factors (Trenor et al., 2011; Aranda & Pascual, 2001). 
 Factor V is one of several substances that helps blood clots to increase blood 
clotting (Fogelson, & Neeves, 2015), The clotting action of factor V is regulated by 
another protein called the activated protein C dose that does not function well with 
the abnormal factor V suffering protein factor V (Levi & van der Poll, 2013) and 
increase the chance of developing deep vein blood clot (DVT) in the leg or lung 
(pulmonary embolus) (Gruber and Bull, 2012). 
 Oral contraceptives containing estrogen increase the plasma concentrations 
of clotting factors II, VII, X, XII, factor VIII, fibrinogen, and thrombin activatable 
fibrinolysis inhibitor (TAFI, but in a different manner (Afsar et al.,2008). Desogestrel 
containing oral contraceptives confers the most significant impact when compared to 
a second-generation oral contraceptive containing levonorgestrel these facts explain 
the increase in factor VII concentrations ( Vinogradova et al.,2014). 
 The decrease in factor V may appear to be beneficial, necessary for the 
activation of prothrombin (II) to thrombin (IIa). Factor V works synergistically with 
protein S to inhibit factor VIII, Estrogen, like many lipophilic hormones, affects the 
gene transcription of various proteins it increases plasma concentrations by crosses 
the cell membrane for a particular target tissue, which there are many that estrogen 
influence, and once inside the cytoplasm binds to nuclear receptors. The 
estrogen/nuclear receptor complex then travels into the nucleus where it recognizes 
and binds to specific recognition sites, called hormone response elements or, in this 
case, estrogen response elements. This binding then turns on gene transcription by 
allowing RNA polymerase II to transcribe the protein in that region of the DNA; these 
new proteins are the clotting factors and proteins. (Middeldorp et al .,2000). 
 Bergendal and his colleagues studied association venous thromboembolism 
with hormonal contraception and thrombophilic genotype. They found thrombophilic 
genotype such factor V Leiden increased risk of venous thromboembolism in users 
of combined hormonal contraception (Bergendal et al., 2014). Also, pulmonary 
embolism and deep vein thrombosis related to oral contraceptive use and found all 
coagulation profile are standard. FV Leiden is negative. CT shows pulmonary 
embolism and discus it by venous thromboembolism arise from the acquired 
condition. Oral contraceptive is one of the purchased risk factors. (Kim and Kim, 
2013) 
 Detection of factor V Leiden mutation by using a multiplex polymerase and 
found there no mutation in all subjects and risk factors are the most significant effect 
patients were oral contraceptive (Ibrahim et al., 2018). 
 Difference between the above studies and this study, here we try to detect 
mutation in factor V among women using oral contraceptives that may act as one of 
the possible risk factors that increase susceptibility to develop thrombosis among 
them. The purpose of this research was to determine the impact of oral contraceptive 
pills on factor V sufferers. 
 
MATERIALS AND METHOD 
 This research was a prospective case-control study conducted at women use 
oral contraceptives during the period from April to November 2018. Fifty women use 
oral contraceptive (case group), and 50 women did not use any contraceptive 
(control group) enrolled in this study. As well as any women had coagulation 
problem, last time exposure to bleeding, thrombosis, or take vitamin effect on 
coagulation system were excluded from this study. 
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Sampling and data collection 
 Three ml of venous blood was collected from each participant in the study 
using the disposable sterile syringe after disinfected the collection site with70% 
alcohol then the blood was dispensed in a sterile EDTA blood container. Data were 
obtained by direct interviewing using a well-structured questionnaire. 
DNA extraction 
 DNA was extracted from whole blood using Guanidine hydrochloride, 4 ml of 
red blood lysis buffer (RCLB) added to each sample, then centrifuged for 5 min at 
6000 rpm, this step repeated two times until a clear pellet of white blood cell have 
appeared, the supernatant was discard and(2 ml of white blood lysis buffer (WCLB), 
1ml of guanidine hydrochloride, 300 of ammonium acetate (NH4) and 10µl of 
proteinase K) were added, then were incubated overnight at 37Cº. After overnight 
incubation, the sample cooled at room temperature. Then 2ml of pre-chilled 
chloroform were added after that samples were centrifuge for 5 min at 6000rpm, 
upper layer collected to new falcon tube contained 10 ml of absolute cold ethanol, 
and then were incubated overnight at -20Cº.After overnight incubation, the sample 
was centrifugated for 10 min at 6000rpm, the supernatant drained, pellet washed 
with 4ml 70% ethanol, then were centrifuged for 10 min at 6000 rpm, and 
supernatant poured off. Pellet was allowed to dry; then, the pellet was dissolved in 
100µlof double distilled water (DDW)and incubated at 4Cºuntil used (Chomczynski et 
al., 2006). 
PCR reaction 
 Each Polymerase Chain Reaction PCR (Techne 312 thermocycler, England), 
reaction was performed using (Eppendorf master cycler) in a final volume of 20 
containers (2.5Mm dNTPs, two target DNA.1(10pmol) of each primer(C, N, M) and 
2.5U (5U/) of Taq polymerase, followed by thermal cycler (Eppendorf master cycler) 
samples ARMS performed PCR reaction for Factor V Leiden, the wild-type primer is 
5, GGACAAATACCT GTATTCC3, the mutant primer is 5, GGACAAATAC 
CTGTATTCCTT3 and the standard primer is 5CTTTCA GGCAGGAACACC3. 
Thermal cycling conditions consisting of 5 min denaturation at 95Co followed by 35 
denaturation cycles at 95Co for the 30s, annealing at 60oC for 30s, extension at 
68Co for 60s, then final extension at 72Co for 5 min, maintained at 4Co for use. The 
PCR reaction was treated with ethidium bromide on 2% agarose gel at 150 V for 45 
minutes (Dajani et al., 2013). 
Ethical considerations 
 Ethical approval obtained from the College of Medical Laboratory Committee, 
Sudan University of Science and Technology, Khartoum, Sudan Ethical approval No 
(MLS–IEC-02-17) Participants were verbally informed, in their simple language, 
about the research, its benefits, and the method of collecting the samples, and then 
their participation approval and publication of the data were obtained. 
Statistical analysis 
 The statistical analysis of the result conducted using the Quantitative Package 
for Social Sciences (SPSS) version 16 for the interpretation of the results, a 
significant difference of less than 0.05 calculated using the Chi-square method. 
 
RESULTS AND DISCUSSION 
 The study conducted to determine the subsequent effect of oral contraceptive 
on factor V gene includes 50 women using oral contraceptive age of the participating 
patient and a corresponding group of fifty healthy women who do not use oral 
contraceptive pills or other contraceptives. 
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 Both participants have no drug effect on hemostatic parameters and have no 
prior thrombosis or family history of bleeding or thrombosis. Participant's research 
classified in less than 20 (20-35) and more than 35 years by age in three groups. 
Based on the results, mean ± StD (30± 5.5 and 29±8.0) in the case and control, 
respectively, with insignificant P.value=0.52. The overall frequency in the case group 
showed that the higher rate 19 (38.5%) were in women with more than three children 
(multi grand), while the lower frequency 3 (6.5%) were in women with one child 
(primary).  
 In contrast, the higher rate of 19 (38.5%) were in women with two (secondary) 
and three (multi) children for each among the control group (table 1). Women those 
used Levonorgestrel were more frequent 44 (88.5%) than those used Dosogestrel 6 
(12.5) (table 1). The age group of (20-35) years was the most frequent, while less 
than 20 years were the lowest constant (table. 1). The result of PCR showed that all 
samples give a reaction in wild type (normal); the mutant type was absent in all 
participants (figure 1).  
  
Table1:Distribution of Demographic Data among Subjects 
 
Variable Case (%) Control (%) 
Gravity 
Primary (one child) 3 (6.5) 4 (8.5) 
Secondary (two child) 14 (28.5) 19 (38.5) 
Multi (three child) 14 (28.5) 19 (38.5) 
Grand multi (more than three child) 19 (38.5) 8 (16.5) 
Type of oral contraceptive 
Levonorgestrel 44 (88.5) - 
Desogestrel 6 (12.5) - 
Age group 
>20 2 (4.5) 6 (12.5) 
20-35 40 (80.5) 31 (62.5) 
< 35 8 (16.5) 13 (26.5) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: The PCR product for a participant, the lane one ladder 50 pb, N= normal 
(wild type), M=mutant, 2 – 16 PCR product. 
 
 The factor V gene is located on chromosome 1q23 and contains 25 exons. 
The factor V gene defect occurs in exon ten where there is a G-A substitution at 
N       M       N       M     N     M      M     M         N       M       N       M       N       M        
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nucleotide 1691, this study showed that there no significant change on factor V, this 
agreement with study of Ibrahim found there was no mutation in FV, but disagree in 
that most considerable affect patient in age 18-45 was oral contraceptive and in this 
study there no significant effect in period (P.value=0.5243) and there no correlation 
with mutation and other risk factors (age, gravity)[8]. Also agree with study done by 
Piparva, on deep vein thrombosis in women taking oral contraceptive and notice that 
woman taking oral combined contraceptive for 3-5 months, developed DVT 
thrombosis of left leg, hereditary and acquired causes of DVT excluded (there no 
mutation in factor V) and believe that risk of blood clot due to dose of estrogen 
(Piparva et al., 2011). 
 In present study duration of use oral contraceptive found most cases use oral 
contraceptive for more than one year this mean use of oral contraceptive for long 
time act as protection by decrease risk of thrombosis this agrees with study of 
Martinelli that was divided case group into three (short less than year, long (1-5) 
year, very long more than five years) and found the risk of VTE in oral contraceptive 
user decrease over time (Martinelli et al., 2016) 
 In our study most of the cases use levonorgestrel that means this type of oral 
contraceptive not cause or have lower effect, this agree to with Vinogradova study 
risk of venous thromboembolism and exposure to combined oral contraceptive and 
found that type of progestogen hormone (drospirenone, desogestrel, gestodene, and 
cyproterone) were associated with increased risk of venous thromboembolism when 
compared to pill containing older progestogen (levonorgestrel and norethisterone) 
(Vinogradova et al., 2014). 
 Effect of oral contraceptive increased probability of VTE development depend 
on dose in medication and type of contraceptive used (Wolski, 2014). Limitation in 
this study summarized in difficulties to collect large sample size due to limited period 
of research and most of the women used more than one type of contraceptives 
irregular, that may interfere and made difficulties to collect it, as well as the high cost 
of PCR primers, acts as barriers made difficulties to use other advanced techniques   
 
CONCLUSION 
 The study concludes that the oral contraceptive pill did not affect factor V, and 
there no correlation between mutation and another risk factor (age, gravity), among 
Sudanese women. The risk-benefit calculations may alter completely for prophylactic 
interventions that carry no penalty, even if they are less active. 
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